Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors?

  • Oncotarget. 2018 Dec 18;9(99):37280-37281. doi: 10.18632/oncotarget.26460.
Toby A Eyre  1
Affiliations
  • 1. Toby A. Eyre: Early Phase Trials Unit, University of Oxford, Oxford, UK; Department of Clinical Haematology, Oxford Cancer Centre, Churchill Hospital, Oxford, UK.
PMID: 30647865 DOI: 10.18632/oncotarget.26460
Keywords
CXD101; HDAC inhibitor; HR23B; Hodgkin lymphoma; T cell lymphoma.
Products